Gaining Analyst Coverage, Institutional Investment and Increasing Valuation

This animal health company fell out of favor with the investment community and lost analyst coverage following multiple regulatory setbacks. We worked with the company to reintroduce them to the street, rebuild credibility and expand their investor base ahead of forthcoming FDA approvals.

Strategy & Tactics
  • We revamped the Company’s IR materials in order to effectively communicate its competitive advantages / growth prospects and capitalize on interest in the sector.
  • We identified sell-side analysts covering the industry, both at large banks and boutique shops, and facilitated introductions.
  • We arranged over 30 sell side meetings in the first two years: Gabelli, Dawson James, Ladenburg, FBR, JPM, OPCO, HCW, Raymond James, Piper, Cowen, Lake Street, Piper, Evercore
  • We set up more than 50 buy side meetings during the same period: Basu Capital, GRT Capital, SIT Investments and 2 NDRSs (24 Meetings)
  • We obtained invitations to several investor conferences, helpings to raise visibility within the sector.
  • Market cap tripled to >$200 mn & stock price doubled during first two years of client engagement
  • Two sell side analysts we introduced the client to assumed coverage, namely HCW and Ladenburg